Increased Risk of Meningococcal Disease Among Young Adults
Younger adults, particularly those enrolled in universities, are facing a heightened risk of meningococcal meningitis and septicaemia. Recent data from the UK Health Security Agency (UKHSA) has revealed that Meningitis B (MenB) was responsible for an astounding 97% of invasive meningococcal disease cases in individuals aged 15 to 24 in England during the period of 2025 to 2026, accounting for 93 out of 96 confirmed cases.
In light of these findings, UKHSA is advising first-year university students to ensure they receive two doses of the MenB vaccine before the start of the academic term. This precaution is crucial, as first-year students are at a significantly greater risk—approximately seven times higher—of contracting meningococcal disease compared to their peers who are not attending university.
Importance of Timely Vaccination for Young Children
The recently published Invasive Meningococcal Disease (IMD) report for England also highlights the prevalence of MenB across various age groups under 25. Among infants, MenB accounted for 92% of cases (34 out of 37), and it was the sole cause in all cases (100%) for children aged 1 to 4 years (35 out of 35). This underscores the necessity for parents to ensure that their infants receive all three doses of the MenB vaccine on schedule as part of the national Childhood Programme. Timely vaccination is the most effective method of safeguarding young children during an age when they are particularly vulnerable to infection.
Recent Outbreaks and Their Consequences
Meningococcal disease is a serious condition, with the IMD report noting 26 fatalities among the 348 total confirmed cases during the year. In March 2026, a notable outbreak of MenB in Kent affected 21 students and other young adults in the Canterbury area. This was followed by two additional outbreaks in Dorset and Berkshire, each involving three or more cases. Tragically, these outbreaks resulted in three deaths, with some survivors now facing long-term health issues.
In response to these alarming outbreaks, a one-time, limited MenB vaccination initiative was launched this summer, specifically targeting school leavers and first-year university students who are at the highest immediate risk of MenB disease.
Vaccination Efforts and Call to Action
As of 31 August 2026, the NHS has administered 246,089 doses of the MenB vaccine to young individuals. However, many more school leavers and first-year undergraduates remain eligible for vaccination as freshers’ week approaches. As students begin to mix closely with new peers in shared living spaces and social settings, the risk of contracting meningococcal bacteria increases.
Eligible students are strongly encouraged to receive both doses of the MenB vaccine promptly and to familiarise themselves with the signs and symptoms of meningitis, ensuring they can recognise the warning signs in themselves and their friends.
Expert Opinions on the Necessity of Vaccination
Dr Shamez Ladhani, a Consultant Epidemiologist at UKHSA, emphasised the importance of vaccination during this exciting yet risky time for young people. He stated that close contact with numerous new acquaintances increases the risk of meningococcal disease, as evidenced by the latest statistics. He also highlighted the critical role of the routine childhood MenB vaccine in safeguarding infants and urged all parents to ensure their children receive all three doses on schedule.
Dame Diana Johnson, Minister of State for Public Health and Patient Safety, expressed her satisfaction that nearly 250,000 young people had received their MenB vaccine before starting university. She acknowledged the efforts of NHS staff and pharmacies in facilitating this programme while emphasising the need for continued outreach to ensure that every eligible young person protects themselves against this serious disease.
Addressing the Public Health Challenge
Vinny Smith, Chief Executive of the Meningitis Research Foundation, reiterated the urgency for every eligible young person in England to take advantage of the time-sensitive MenB vaccine offer from the NHS. He noted that this year’s vaccination programme is a vital step toward bridging the protection gap for teenagers and young adults, an age group that continues to experience a troubling number of cases.
Dr Tom Nutt, Chief Executive of Meningitis Now, also highlighted the ongoing threat posed by meningitis, particularly Meningitis B, which accounted for 97% of cases among 15 to 24-year-olds in England last year. He cautioned students against underestimating the risk, as meningitis can develop rapidly and have life-altering effects. Vaccination remains the most effective defence against this serious illness.
Recognising Symptoms and Seeking Help
While the MenB vaccine offers protection against many strains of meningococcal disease, it does not cover all infections that can lead to meningitis and septicaemia. It is vital for young people to remain vigilant about recognising the symptoms associated with these conditions. Early medical intervention can be lifesaving, and individuals experiencing symptoms such as high fever, cold extremities, vomiting, confusion, rapid breathing, muscle and joint pain, discoloured skin, headaches, and a stiff neck should seek immediate medical advice.
In addition to MenB, other strains of meningococcal bacteria, namely A, C, W, and Y, can also lead to meningitis and septicaemia among young individuals. The MenACWY vaccine is routinely offered to teenagers as part of the school immunisation programme, and all teenagers remain eligible for MenACWY vaccination until their 25th birthday. It is crucial for those entering higher education institutions to take advantage of this offer, especially given the heightened risk they face.
For further information on meningococcal disease and vaccination options, individuals can refer to the NHS resources on the MenB vaccine for children and arrange appointments to check eligibility for the MenB vaccination. Additional advice and support can be found through dedicated resources on meningitis for students.